US-based Boston Scientific has announced a limited market release of its WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems.
The portfolio has four MRI conditional, Bluetooth-enabled rechargeable and non-rechargeable implantable pulse generators (IPGs), which can be personalised.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In addition, it provides Fast Acting Sub-perception Therapy (FAST) to deliver paresthesia-free pain relief in minutes.
Compared with traditional paresthesia-free treatments that take days to provide pain relief, FAST therapy targets a novel SCS mechanism of action to provide immediate relief.
Duke University biomedical engineering professor Warren Grill said: “We have found that the specific targeting and stimulation parameters of FAST uniquely engage the surround inhibition mechanism to produce rapid and robust pain relief.”
These systems are supported by the Cognita Solutions suite of digital tools for patients and physicians.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe WaveWriter Alpha SCS Systems is directed at tackling common challenges in pain management such as raising awareness about drug-free pain management options, aiding patients in finding local physicians, and also helping physicians in sustaining long-term functional outcomes for patients.
Boston Scientific Neuromodulation senior vice-president and president Maulik Nanavaty said: “It is with great enthusiasm that we embark on the next era of personalisation with the WaveWriter Alpha SCS Systems.
“Combined with our family of innovative and proven solutions for the treatment of chronic pain, including the Vertiflex Procedure and radiofrequency ablation, we are helping physicians provide treatments that span the continuum of care so patients can find access to the medical support they need to live better lives.”
Last December, the systems received approval from the US Food and Drug Administration (FDA).
It is indicated for managing chronic intractable pain of the trunk and / or limbs, including unilateral or bilateral pain linked to failed back surgery syndrome, Complex Regional Pain Syndrome Types I and II, intractable low back pain, and leg pain.
